Ella Fitszimmons
Sep 10, 2008

Xian Janssen shifts two brands to Bates141

BEIJING - Bates141 has secured the creative duties for two of Johnson & Johnson subsidiary Xian Janssen Pharmaceutical's over-the-counter products, following a pitch contested by two other agencies.

Xian Janssen shifts two brands to Bates141
DMG was the incumbent for Motilium, which has a reported media spend of US$30 million, though it could not be confirmed whether it attempted to defend the account.

Motilium (a stomach motility drug) is currently the most successful OTC medication across categories in China. The second brand, Mylanta, is a new antacid.

Source:
Campaign China

Related Articles

Just Published

8 hours ago

Times of India launches 'My City, My Art' challenge ...

Participants are encouraged to unleash their creativity by reimagining their cities through artistic expression.

8 hours ago

Goafest unveils 'age of adaptability' theme for 2024

A chameleon has been selected as the 2024 event mascot, symbolising the industry's need to continuously evolve in response to changing environments.

8 hours ago

Scope3: A third of web domains feature ‘problematic’...

EXCLUSIVE: Ad spend wastage goes beyond made-for-advertising websites, finds digital emissions startup.